• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
mRNA vaccine boosters and impaired immune system response in immune compromised individuals: a narrative review.免疫功能低下个体中的mRNA疫苗加强针与免疫系统反应受损:一篇叙述性综述
Clin Exp Med. 2024 Jan 27;24(1):23. doi: 10.1007/s10238-023-01264-1.
2
Low switched memory B cells are associated with no humoral response after SARS-CoV-2 vaccine boosters in kidney transplant recipients.低转换记忆 B 细胞与肾移植受者接种 SARS-CoV-2 疫苗加强针后无体液免疫反应相关。
Front Immunol. 2023 Oct 24;14:1202630. doi: 10.3389/fimmu.2023.1202630. eCollection 2023.
3
Humoral and cellular immune durability of different COVID-19 vaccine platforms following homologous/heterologous boosters: one-year post vaccination.同源/异源加强接种后不同新冠疫苗平台的体液免疫和细胞免疫持久性:接种后一年
Front Immunol. 2025 Jan 22;16:1526444. doi: 10.3389/fimmu.2025.1526444. eCollection 2025.
4
Exponential decline, ceiling effect, downregulation, and T-cell response in immunoglobulin G antibody levels after messenger RNA vaccine boosters: a case report.信使核糖核酸疫苗加强针接种后免疫球蛋白G抗体水平的指数下降、天花板效应、下调及T细胞反应:一例报告
J Med Case Rep. 2024 Dec 20;18(1):631. doi: 10.1186/s13256-024-04889-2.
5
Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.一种自我扩增 RNA COVID-19 疫苗(ARCT-154)与 BNT162b2 mRNA COVID-19 疫苗加强针的免疫原性和安全性:一项双盲、多中心、随机、对照、3 期、非劣效性试验。
Lancet Infect Dis. 2024 Apr;24(4):351-360. doi: 10.1016/S1473-3099(23)00650-3. Epub 2023 Dec 20.
6
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.BNT162b2 和 mRNA-1273 新冠疫苗作为两剂 ChAdOx1 nCoV-19 或 BNT162b2 疫苗后的第四剂加强针,以及一剂 BNT162b2 疫苗后的第三剂加强针的安全性、免疫原性和反应原性:一项多中心、盲法、2 期、随机试验。
Lancet Infect Dis. 2022 Aug;22(8):1131-1141. doi: 10.1016/S1473-3099(22)00271-7. Epub 2022 May 9.
7
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.在英国,两剂 ChAdOx1 nCov-19 或 BNT162b2 疫苗接种后,作为第三剂加强针接种 7 种 COVID-19 疫苗后免疫原性的持久性:COV-BOOST 试验的三个月分析。
J Infect. 2022 Jun;84(6):795-813. doi: 10.1016/j.jinf.2022.04.018. Epub 2022 Apr 9.
8
Current German Recommendations and International Research on the Use of COVID-19 Boosters among Health Care Providers in 2024: A Narrative Review.2024 年德国当前推荐意见和国际医疗保健提供者使用 COVID-19 加强针的研究:叙事性综述。
Medicina (Kaunas). 2024 Feb 25;60(3):385. doi: 10.3390/medicina60030385.
9
Defining Clinical and Immunological Predictors of Poor Immune Responses to COVID-19 mRNA Vaccines in Patients with Primary Antibody Deficiency.定义原发性抗体缺陷患者对 COVID-19 mRNA 疫苗免疫反应不良的临床和免疫学预测因子。
J Clin Immunol. 2022 Aug;42(6):1137-1150. doi: 10.1007/s10875-022-01296-4. Epub 2022 Jun 17.
10
Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial.奥密克戎 BA.1 含mRNA-1273 加强针与英国原始 COVID-19 疫苗的比较:一项随机、观察者盲、活性对照试验。
Lancet Infect Dis. 2023 Sep;23(9):1007-1019. doi: 10.1016/S1473-3099(23)00295-5. Epub 2023 Jun 19.

引用本文的文献

1
Cytogenetic Alterations Observed in Exfoliative Cells of the Tongue and Oral Mucosa of SARS-CoV-2-Vaccinated Patients: Report of Two Cases and a Brief Literature Review.在接种新冠病毒疫苗患者的舌部和口腔黏膜脱落细胞中观察到的细胞遗传学改变:两例报告及文献简要综述
Rev Soc Bras Med Trop. 2025 Jun 2;58:e008042025. doi: 10.1590/0037-8682-0008-2025. eCollection 2025.
2
Diagnostic and Therapeutic Challenges in Lyme Disease and Co-Infections: Unraveling Neuropsychiatric and Neurological Complexities-A Comprehensive Case Series Analysis.莱姆病及合并感染的诊断与治疗挑战:揭示神经精神和神经复杂性——一项综合病例系列分析
Integr Med (Encinitas). 2025 Jun;24(3):10-27.
3
Jembrana disease in Indonesia: An updated review.印度尼西亚的杰姆巴纳病:最新综述。
Open Vet J. 2025 Mar;15(3):1091-1100. doi: 10.5455/OVJ.2025.v15.i3.3. Epub 2025 Mar 31.
4
The Role of Memory T-Cell Mediated Immunity in Long-term COVID-19: Effects of Vaccination Status.记忆性T细胞介导的免疫在长期新冠中的作用:疫苗接种状态的影响
Iran J Med Sci. 2025 Feb 1;50(2):61-68. doi: 10.30476/ijms.2024.104003.3744. eCollection 2025 Feb.
5
Evolution of SARS-CoV-2 T cell responses as a function of multiple COVID-19 boosters.作为多次新冠病毒加强针接种函数的新冠病毒 2 型 T 细胞反应的演变
bioRxiv. 2025 Jan 9:2025.01.08.631842. doi: 10.1101/2025.01.08.631842.
6
Durability of Adaptive Immunity in Immunocompetent and Immunocompromised Patients Across Different Respiratory Viruses: RSV, Influenza, and SARS-CoV-2.免疫功能正常和免疫功能低下患者针对不同呼吸道病毒(呼吸道合胞病毒、流感病毒和严重急性呼吸综合征冠状病毒2)的适应性免疫持久性
Vaccines (Basel). 2024 Dec 22;12(12):1444. doi: 10.3390/vaccines12121444.
7
A comprehensive review of paratuberculosis in animals and its implications for public health.动物副结核病综合综述及其对公共卫生的影响。
Open Vet J. 2024 Nov;14(11):2731-2744. doi: 10.5455/OVJ.2024.v14.i11.2. Epub 2024 Nov 30.
8
Clinical development of SpikoGen®, an Advax-CpG55.2 adjuvanted recombinant spike protein vaccine.SpikoGen®,一种 Advax-CpG55.2 佐剂的重组刺突蛋白疫苗的临床开发。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2363016. doi: 10.1080/21645515.2024.2363016. Epub 2024 Jun 5.
9
Current German Recommendations and International Research on the Use of COVID-19 Boosters among Health Care Providers in 2024: A Narrative Review.2024 年德国当前推荐意见和国际医疗保健提供者使用 COVID-19 加强针的研究:叙事性综述。
Medicina (Kaunas). 2024 Feb 25;60(3):385. doi: 10.3390/medicina60030385.

本文引用的文献

1
Effectiveness of the Coronavirus Disease 2019 Bivalent Vaccine.2019年冠状病毒病二价疫苗的有效性。
Open Forum Infect Dis. 2023 Apr 19;10(6):ofad209. doi: 10.1093/ofid/ofad209. eCollection 2023 Jun.
2
IgG4 Antibodies Induced by Repeated Vaccination May Generate Immune Tolerance to the SARS-CoV-2 Spike Protein.重复接种疫苗诱导产生的IgG4抗体可能会对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白产生免疫耐受。
Vaccines (Basel). 2023 May 17;11(5):991. doi: 10.3390/vaccines11050991.
3
COVID-19, post-acute COVID-19 syndrome (PACS, "long COVID") and post-COVID-19 vaccination syndrome (PCVS, "post-COVIDvac-syndrome"): Similarities and differences.新型冠状病毒肺炎、新型冠状病毒肺炎后综合征(PACS,“长新冠”)和新型冠状病毒肺炎疫苗接种后综合征(PCVS,“新冠疫苗后综合征”):相似性和差异。
Pathol Res Pract. 2023 Jun;246:154497. doi: 10.1016/j.prp.2023.154497. Epub 2023 May 3.
4
Evolving Real-World Effectiveness of Monoclonal Antibodies for Treatment of COVID-19 : A Cohort Study.不断演变的 COVID-19 治疗用单克隆抗体的真实世界疗效:一项队列研究。
Ann Intern Med. 2023 Apr;176(4):496-504. doi: 10.7326/M22-1286. Epub 2023 Apr 4.
5
Effectiveness of second booster compared to first booster and protection conferred by previous SARS-CoV-2 infection against symptomatic Omicron BA.2 and BA.4/5 in France.与首次加强针相比,第二次加强针的有效性,以及既往感染 SARS-CoV-2 对法国奥密克戎 BA.2 和 BA.4/5 症状的保护作用。
Vaccine. 2023 Apr 24;41(17):2754-2760. doi: 10.1016/j.vaccine.2023.03.031. Epub 2023 Mar 21.
6
Viral Population Heterogeneity and Fluctuating Mutational Pattern during a Persistent SARS-CoV-2 Infection in an Immunocompromised Patient.免疫功能低下患者持续性 SARS-CoV-2 感染期间的病毒群体异质性和突变模式波动。
Viruses. 2023 Jan 19;15(2):291. doi: 10.3390/v15020291.
7
Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases, in Patients with Cardiac Issues, and in the Healthy Population.新型冠状病毒肺炎疫苗在自身免疫性疾病患者、有心脏问题的患者及健康人群中的安全性
Pathogens. 2023 Feb 2;12(2):233. doi: 10.3390/pathogens12020233.
8
Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination.经重复 SARS-CoV-2 mRNA 疫苗接种后向非炎症性、刺突特异性 IgG4 抗体的类别转换。
Sci Immunol. 2023 Jan 27;8(79):eade2798. doi: 10.1126/sciimmunol.ade2798.
9
Extended SARS-CoV-2 RBD booster vaccination induces humoral and cellular immune tolerance in mice.扩展的严重急性呼吸综合征冠状病毒2受体结合域加强疫苗接种可诱导小鼠产生体液和细胞免疫耐受。
iScience. 2022 Dec 22;25(12):105479. doi: 10.1016/j.isci.2022.105479. Epub 2022 Nov 2.
10
Autoimmune and autoinflammatory conditions after COVID-19 vaccination. New case reports and updated literature review.接种 COVID-19 疫苗后的自身免疫和自身炎症性疾病。新病例报告和最新文献回顾。
J Autoimmun. 2022 Oct;132:102898. doi: 10.1016/j.jaut.2022.102898. Epub 2022 Aug 24.

免疫功能低下个体中的mRNA疫苗加强针与免疫系统反应受损:一篇叙述性综述

mRNA vaccine boosters and impaired immune system response in immune compromised individuals: a narrative review.

作者信息

Boretti Alberto

机构信息

Melbourne Institute of Technology, The Argus, 288 La Trobe St, Melbourne, VIC 3000, Australia.

出版信息

Clin Exp Med. 2024 Jan 27;24(1):23. doi: 10.1007/s10238-023-01264-1.

DOI:10.1007/s10238-023-01264-1
PMID:38280109
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10821957/
Abstract

Over the last 24 months, there has been growing evidence of a correlation between mRNA COVID-19 vaccine boosters and increased prevalence of COVID-19 infection and other pathologies. Recent works have added possible causation to correlation. mRNA vaccine boosters may impair immune system response in immune compromised individuals. Multiple doses of the mRNA COVID-19 vaccines may result in much higher levels of IgG 4 antibodies, or also impaired activation of CD4 + and CD8 + T cells. The opportunity for mRNA vaccine boosters to impair the immune system response needs careful consideration, as this impacts the cost-to-benefit ratio of the boosters' practice.

摘要

在过去24个月里,越来越多的证据表明,新冠病毒mRNA疫苗加强针与新冠病毒感染率上升及其他病症之间存在关联。最近的研究在这种关联的基础上增加了可能的因果关系。mRNA疫苗加强针可能会损害免疫功能低下个体的免疫系统反应。多剂新冠病毒mRNA疫苗可能会导致IgG 4抗体水平大幅升高,或者也会损害CD4 +和CD8 + T细胞的激活。mRNA疫苗加强针损害免疫系统反应的可能性需要仔细考虑,因为这会影响加强针接种做法的成本效益比。